A Study of Tazemetostat in Combination With Various Treatments in Participants With Blood Cancer.
Summary
This trial will study how safely the tazemetostat works with other therapies in various hematological malignancies. Hematologic malignancies are cancers that most often begin in the bone marrow or lymph nodes where blood precursors are produced. They are often called blood cancers and fall into three categories: leukemia, lymphoma and myeloma. Tazemetostat has been found to be a safe and effective drug that works in patients with follicular lymphoma where the disease has come back after treatment (known as relapsed) and when other treatment no longer works (known as refractory). Combining tazemetostat with other treatments may work better in treating patients with hematological malignancies and may improve disease response and durability of response.
Timeline
- Start
- 2021-12-22
- Primary completion
- 2023-07-05
- Completion
- 2023-07-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Acalabrutinib | Small molecule | 100 mg | Oral |
| Comparator | Daratumumab | Monoclonal antibody | 16 mg/kg | Intravenous |
| Comparator | Daratumumab | Monoclonal antibody | 1800 mg | Intravenous |
| Comparator | Dexamethasone | Small molecule | 20 mg | Oral |
| Comparator | Dexamethasone | Small molecule | 40 mg | Oral |
| Comparator | Lenalidomide | Other / unclassified | 10 mg | Oral |
| Comparator | Lenalidomide | Other / unclassified | 20 mg | Oral |
| Comparator | Mosunetuzumab | Monoclonal antibody | 45 mg | Subcutaneous |
| Comparator | Pomalidomide | Other / unclassified | 4 mg | Oral |
| Comparator | Tafasitamab | Monoclonal antibody | 12 mg/kg | Intravenous |
| Comparator | Tazemetostat | Small molecule | — | Oral |
| Comparator | rHuPH20 | Protein / enzyme biologic | 30000 iu | Subcutaneous |